Literature DB >> 11448173

Highly sulfated forms of heparin sulfate are involved in japanese encephalitis virus infection.

C M Su1, C L Liao, Y L Lee, Y L Lin.   

Abstract

Japanese encephalitis virus (JEV) infects a broad range of cell types in vitro, though little is known about the initial events of JEV infection. In the present study, we found that highly sulfated glycosaminoglycans (GAGs) are involved in infection of both neurovirulent (RP-9) and attenuated (RP-2ms) JEV strains. Competition experiments using highly sulfated GAGs, heparin and dextran sulfate, demonstrated an inhibition of JEV's attachment and subsequent infection of BHK-21 cells. Treatment of target cells by a potent sulfation inhibitor, sodium chlorate, greatly reduced viral binding ability as well as infection, suggesting a critical role of GAGs' sulfation status on the cellular surface in JEV infection. This phenomenon was confirmed by the manifestation of a distinct binding efficiency of JEV to the wild-type CHO cell line and its mutants with defects in GAG biosynthesis. We also demonstrated the binding of JEV particles and virus envelope glycoprotein to immobilized heparin beads. Furthermore, the addition of heparin suppressed the cytopathic effects induced by JEV infection in cultured cells. Our results establish that the highly sulfated form of GAGs on cell surfaces plays a determining role in the early stage of in vitro JEV infection. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448173     DOI: 10.1006/viro.2001.0986

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  22 in total

Review 1.  Recent advances in Japanese encephalitis.

Authors:  Tom Solomon
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

2.  GRP78 Is an Important Host Factor for Japanese Encephalitis Virus Entry and Replication in Mammalian Cells.

Authors:  Minu Nain; Sriparna Mukherjee; Sonali Porey Karmakar; Adrienne W Paton; James C Paton; M Z Abdin; Anirban Basu; Manjula Kalia; Sudhanshu Vrati
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

3.  Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus.

Authors:  Eva Lee; Mario Lobigs
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 4.  Is heparan sulfate a target for inhibition of RNA virus infection?

Authors:  Jiaxin Ling; Jinlin Li; Asifa Khan; Åke Lundkvist; Jin-Ping Li
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-23       Impact factor: 4.249

5.  Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells.

Authors:  Santanu Bose; Mausumi Basu; Amiya K Banerjee
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

6.  Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses.

Authors:  Eva Lee; Roy A Hall; Mario Lobigs
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

7.  Involvement of ceramide in the propagation of Japanese encephalitis virus.

Authors:  Hideki Tani; Mai Shiokawa; Yuuki Kaname; Hiroto Kambara; Yoshio Mori; Takayuki Abe; Kohji Moriishi; Yoshiharu Matsuura
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

8.  Surfactant-modified nanoclay exhibits an antiviral activity with high potency and broad spectrum.

Authors:  Jian-Jong Liang; Jiun-Chiou Wei; Yi-Ling Lee; Shan-hui Hsu; Jiang-Jen Lin; Yi-Ling Lin
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

9.  The infection of primary avian tracheal epithelial cells with infectious bronchitis virus.

Authors:  Ching-I Shen; Ching-Ho Wang; Jiunn-Wang Liao; Tien-Wang Hsu; Shu-Ming Kuo; Hong-Lin Su
Journal:  Vet Res       Date:  2009-10-01       Impact factor: 3.683

Review 10.  Carbohydrate-related inhibitors of dengue virus entry.

Authors:  Kazuya I P J Hidari; Tomoko Abe; Takashi Suzuki
Journal:  Viruses       Date:  2013-02-06       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.